Compare BRID & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | PRLD |
|---|---|---|
| Founded | 1932 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 69.1M |
| IPO Year | N/A | 2020 |
| Metric | BRID | PRLD |
|---|---|---|
| Price | $8.08 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.4K | ★ 605.6K |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,364,000.00 | $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $7.24 | $0.61 |
| 52 Week High | $10.77 | $4.22 |
| Indicator | BRID | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 47.00 |
| Support Level | $7.65 | $2.37 |
| Resistance Level | $8.50 | $2.99 |
| Average True Range (ATR) | 0.26 | 0.30 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 66.13 | 8.42 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.